63 related articles for article (PubMed ID: 22967431)
1. [Research focus on multiple myeloma at the 53rd American Society of Hematology meeting].
Zhang KJ; Liang R; Wang LH
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):596-8. PubMed ID: 22967431
[No Abstract] [Full Text] [Related]
2. [Mantle cell lymphoma in the era of targeted-therapy-in-depth report on American Society of Hematology 53rd annual meeting].
Liang R; Shi YK; Han XH
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):690-2. PubMed ID: 23134877
[No Abstract] [Full Text] [Related]
3. 2nd International Congress on Leukemia, Lymphoma and Myeloma.
Arat M; Ozsan GH; Yenerel MN; Cetin M; Ozcan M
Expert Rev Hematol; 2009 Oct; 2(5):509-12. PubMed ID: 21083016
[TBL] [Abstract][Full Text] [Related]
4. [Introduction to 51st American Society of Hematology Annual Meeting].
Tang JY; Tang YM; Jiang H
Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):190-3. PubMed ID: 20426954
[No Abstract] [Full Text] [Related]
5. [Hotpots of the 55th American society of hematology annual meeting: red blood cell disorders].
Zhang L; Zhou K; Zhang F
Zhonghua Xue Ye Xue Za Zhi; 2014 May; 35(5):479. PubMed ID: 24857229
[No Abstract] [Full Text] [Related]
6. Clinically relevant end points and new drug approvals for myeloma.
Anderson KC; Kyle RA; Rajkumar SV; Stewart AK; Weber D; Richardson P;
Leukemia; 2008 Feb; 22(2):231-9. PubMed ID: 17972944
[TBL] [Abstract][Full Text] [Related]
7. American Society of Hematology--51st annual meeting & exposition. Part 2.
Shumoogam J; Beecher N
IDrugs; 2010 Feb; 13(2):60-2. PubMed ID: 20127550
[TBL] [Abstract][Full Text] [Related]
8. [Hotspot report of the 54th American Society of Hematology Annual Meeting Drug resistance of multiple myeloma].
Hao M; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):374-6. PubMed ID: 23668218
[No Abstract] [Full Text] [Related]
9. Highlights in myelodysplastic syndromes from the 61st American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 5(2):1-24. PubMed ID: 33843919
[No Abstract] [Full Text] [Related]
10. Highlights in Hodgkin lymphoma from the 61st American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 6(2):1-24. PubMed ID: 33843909
[No Abstract] [Full Text] [Related]
11. Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition.
Clin Adv Hematol Oncol; 2021 Feb; 19 Suppl 7(2):1-24. PubMed ID: 33843921
[No Abstract] [Full Text] [Related]
12. Highlights in myelodysplastic syndromes from the 61st American Society of Hematology Annual Meeting: commentary.
Garcia-Manero G
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 5(2):18-22. PubMed ID: 33843920
[No Abstract] [Full Text] [Related]
13. Highlights in Hodgkin lymphoma from the 61st American Society of Hematology Annual Meeting: commentary.
Straus DJ
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 6(2):20-23. PubMed ID: 33843910
[No Abstract] [Full Text] [Related]
14. Highlights in myelodysplastic syndromes from the 62nd American Society of Hematology Annual Meeting and Exposition.
Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 5(1):1-24. PubMed ID: 33843865
[No Abstract] [Full Text] [Related]
15. Highlights in CAR T-cell therapy from the 61st American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 7(2):1-24. PubMed ID: 33843871
[No Abstract] [Full Text] [Related]
16. Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
Evens AM
Clin Adv Hematol Oncol; 2021 Feb; 19 Suppl 7(2):20-23. PubMed ID: 33843922
[No Abstract] [Full Text] [Related]
17. Highlights in B-cell malignancies from the 61st American Society of Hematology Annual Meeting: commentary.
Furman RR
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 8(2):24-26. PubMed ID: 33843883
[No Abstract] [Full Text] [Related]
18. Highlights in myelodysplastic syndromes from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
Garcia-Manero G
Clin Adv Hematol Oncol; 2021 Jan; 19 Suppl 5(1):20-23. PubMed ID: 33843866
[No Abstract] [Full Text] [Related]
19. Highlights in CAR T-cell therapy from the 62nd American Society of Hematology Annual Meeting and Exposition.
Clin Adv Hematol Oncol; 2021 Mar; 19 Suppl 10(3):1-24. PubMed ID: 33843917
[No Abstract] [Full Text] [Related]
20. Highlights in CAR T-cell therapy from the 61st American Society of Hematology Annual Meeting: commentary.
Jacobson CA
Clin Adv Hematol Oncol; 2020 Feb; 18 Suppl 7(2):20-23. PubMed ID: 33843872
[No Abstract] [Full Text] [Related]
[Next] [New Search]
